HUM Stock Analysis – Expert Insights for Potential Investors

By Naomi Wentworth • Monday, October 20 15:24 • Permanent Link

Large-cap Health Care company Humana has moved 2.6% so far today on a volume of 571,744, compared to its average of 1,955,373. In contrast, the S&P 500 index moved 1.0%.

Humana trades -4.47% away from its average analyst target price of $295.38 per share. The 24 analysts following the stock have set target prices ranging from $235.0 to $353.0, and on average have given Humana a rating of hold.

Anyone interested in buying HUM should be aware of the facts below:

Humana's current price is 61.8% above its Graham number of $174.42, which implies that at its current valuation it does not offer a margin of safety
Humana has moved 5.5% over the last year, and the S&P 500 logged a change of 13.8%
Based on its trailing earnings per share of 13.06, Humana has a trailing 12 month Price to Earnings (P/E) ratio of 21.6 while the S&P 500 average is 29.3
HUM has a forward P/E ratio of 16.8 based on its forward 12 month price to earnings (EPS) of $16.84 per share
Its Price to Book (P/B) ratio is 1.86 compared to its sector average of 3.19
Humana Inc. provides medical and specialty insurance products in the United States.
Based in Louisville, the company has 65,680 full time employees and a market cap of $33.94 Billion. Humana currently returns an annual dividend yield of 1.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.